| Titre | | nb de chargement | |
|---|
| Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration | | 14779 | |
| Transgene reçoit l'autorisation de lancer un essai de Phase I avec TG6050, un virus oncolytique innovant armé avec de l'IL-12 et administré par voie intraveineuse | | 12391 | |
| Transgene announces Financial Calendar for 2023 | | 11142 | |
| Transgene présente son calendrier de communication financière pour 2023 | | 11588 | |
| Degroof Petercams Virtual Healthcare Conference 27 janvier 2023 | | 16974 | |
| LifeSci Advisors Corporate Access Event - San Francisco, USA - January 9 to 12, 2022 | | 16974 | |
| LifeSci Advisors Corporate Access Event San Francisco, États-Unis - 9 au 12 janvier 2022 | | 16974 | |
| Degroof Petercams Virtual Healthcare Conference January 27, 2023 | | 16974 | |
| 26th ODDO BHF Forum - Virtual - January 9 and 10, 2023 | | 16974 | |
| 26e Forum ODDO BHF - Virtuel - 9 et 10 janvier 2023 | | 16974 | |
| Invest Securities Biomed Forum - January 24, 2023 | | 16974 | |
| Invest Securities Biomed Forum - 24 janvier 2023 | | 16974 | |
| Transgene Announces Upcoming Investor Meetings | | 19213 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 17599 | |
| __cf_bm | | 16974 | |
| vuid | | 16974 | |
| _pk_ses.1.9651 | | 16974 | |
| _pk_id.1.9651 | | 16974 | |
| JSESSIONID | | 16974 | |
| CookieLawInfoConsent | | 16974 | |
| viewed_cookie_policy | | 16974 | |
| cookielawinfo-checkbox-fonctionnels | | 16974 | |
| cookielawinfo-checkbox-cookies-externes | | 16974 | |
| cookielawinfo-checkbox-analytique | | 16974 | |
| cookielawinfo-checkbox-essentiels | | 16974 | |
| Transgene and BioInvent joint paper on BT-001 wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022 | | 22703 | |
| Transgene et BioInvent remportent le prix du Meilleur Article dans la catégorie Immunothérapie oncolytique et locale décerné par le JITC, pour leurs travaux sur BT-001 | | 18709 | |
| Politique de confidentialité | | 18243 | |
| | 18243 | |
| | 18243 | |
| | 18243 | |
| Cookie policy | | 18243 | |
| privacy policy | | 18243 | |
| POLITIQUE DE CONFIDENTIALITE | | 18243 | |
| PRIVACY POLICY | | 18243 | |
| Transgene reports business update and Q3 2022 financial position | | 18714 | |
| Transgene fait le point sur ses activités et sa situation financière au troisième trimestre 2022 | | 18817 | |
| Politique Cookies de Transgene | | 18243 | |
| COOKIE POLICY | | 18243 | |
| annoncegb4001 | | 18244 | |
| annonce4001 | | 18244 | |
| Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers | | 18733 | |
| Transgene annonce le résultat positif de l'analyse intermédiaire de l'essai de Phase II évaluant TG4001 + Avelumab vs Avelumab seul dans les cancers anogénitaux HPV-positifs | | 21155 | |
| Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas | | 26179 | |
| Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas | | 26179 | |
| R&D Day: Presentations to Highlight Transgene's Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data | | 44007 | |
| Journée R&D : présentations sur le positionnement compétitif de Transgene, sa capacité à concevoir des immunothérapies nouvelles pour les patients atteints de cancer et sur des données cliniques actualisées | | 27097 | |
| annonceR&D | | 28914 | |
| annonceR&D | | 28914 | |
| Transgene R&D Day (Paris, France) | | 30722 | |
| Journée R&D de Transgene Paris | | 30722 | |
| Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 | | 33326 | |
| Les données de Phase I de TG6002 présentées à lESMO 2022 confirment le potentiel des virus oncolytiques Invir.IO de Transgene administrés par voie intraveineuse pour traiter les tumeurs solides | | 34619 | |
| Positive Readouts for Transgene's Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022 | | 31438 | |
| Données cliniques positives pour les candidats-médicaments issus des deux plateformes innovantes de Transgene - Nouveaux résultats attendus au second semestre 2022 | | 31759 | |
| 2022 Half-year results and business update | | 33457 | |
| Résultats financiers du 1er semestre 2022 et point sur lactivité | | 33457 | |
| 2021 Full-year results and business update | | 33457 | |
| Résultats annuels 2021 et point sur lactivité | | 33457 | |
| Transgene announces Upcoming Investor Meetings | | 40674 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 37480 | |
| decompte twitter | | 39849 | |
| Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA® | | 51257 | |
| Transgene et BioInvent annoncent la conclusion d'un accord avec MSD de collaboration clinique et d'approvisionnement pour évaluer BT-001 en combinaison avec KEYTRUDA® | | 45973 | |
| Transgene and BioInvent announce positive progress for BT-001 | | 51024 | |
| Transgene et BioInvent présentent les avancées positives de BT-001 | | 43502 | |
| TG4050 | | 45631 | |
| TG4050 | | 45631 | |
| annonce TG4050en | | 45631 | |
| annonce TG4050 | | 45631 | |
| Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 | | 46826 | |
| Transgene a présenté de nouvelles données de Phase I de TG4050 au congrès de l'ASCO 2022 | | 47901 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 46955 | |
| Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC) | | 46955 | |
| Laurence Espinasse | | 46955 | |
| Laurence Espinasse? | | 46955 | |
| Prof. Jean-Yves Blay? | | 46955 | |
| Pr Jean-Yves Blay | | 46955 | |
| Dr. Alessandro Riva | | 46955 | |
| Dr. Alessandro Riva? | | 46955 | |
| Transgene présentera de nouvelles données préliminaires des essais cliniques de Phase I de TG4050 (plateforme myvac®) au congrès de l'ASCO 2022 | | 55410 | |
| Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022 | | 58149 | |
| Transgene's Combined General Meeting of May 25, 2022 | | 61918 | |
| Assemblée Générale Mixte de Transgene du 25 mai 2022 | | 49317 | |
| Transgene Announces Upcoming Investor Meetings | | 50148 | |
| Transgene annonce ses prochaines rencontres avec les investisseurs | | 49048 | |
| All of Transgene's preclinical and clinical assets progressed in line with expectations in Q1 2022 | | 48814 | |
| Progression de tous les produits précliniques et cliniques de Transgene au premier trimestre 2022 | | 49831 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 48163 | |
| Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination | | 48163 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 48185 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 48185 | |
| Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 | | 56107 | |
| Transgene présente de nouvelles données préliminaires de Phase I confirmant le potentiel de TG4050 au congrès de l'AACR 2022 | | 52011 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 50516 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 50516 | |
| Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF | | 50516 | |
| Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients | | 50516 | |
| Availability of Transgene's 2021 Universal Registration Document | | 58375 | |
| Mise à disposition du document d'enregistrement universel 2021 de Transgene | | 52567 | |
| Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 | | 51505 | |
| Mise à disposition des documents préparatoires à l'Assemblée générale du 25 mai 2022 | | 51609 | |
| Transgene's Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman | | 53922 | |
| Le conseil d'administration de Transgene renforce sa gouvernance et propose la nomination du Dr Alessandro Riva en qualité de Président Indépendant | | 54432 | |
| Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022 | | 65074 | |
| Transgene confirme le potentiel de ses deux plateformes innovantes et attend des résultats cliniques significatifs en 2022 | | 61561 | |
| Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 | | 61727 | |
| Transgene et BioInvent présenteront un poster à l'AACR 2022 sur BT-001, un virus oncolytique innovant | | 54342 | |
| Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 | | 60941 | |
| Transgene présentera des nouvelles données préliminaires positives des Phases I avec TG4050 à l'AACR 2022 | | 53717 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 51682 | |
| BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment | | 51682 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 51682 | |
| Vectorized Treg-depleting ?CTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject "cold" tumors | | 51682 | |
| Éthique et conformité | | 51682 | |
| Corporate governance | | 51682 | |
| Ethics & compliance | | 51682 | |
| Transgene appoints Steven Bloom as Chief Business Officer | | 66576 | |
| Transgene annonce la nomination de Steven Bloom au poste de Directeur du Business Development | | 53689 | |
| Ethics and compliance | | 51682 | |
| Éthique & conformité | | 51682 | |
| Custom Styles | | 51684 | |
| Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade | | 54423 | |
| Transgene et BioInvent publient dans le JITC des données de preuve de concept préclinique du virus oncolytique BT-001 | | 54675 | |
| | 51688 | |
| Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors | | 75661 | |
| Transgene et PersonGen annoncent une collaboration pour l'évaluation d'une nouvelle combinaison thérapeutique contre les tumeurs solides | | 66813 | |
| Transgene announces Financial Calendar for 2022 | | 56880 | |
| Transgene présente son calendrier de communication financière pour 2022 | | 53164 | |
| Transgene annonce ses rencontres avec les investisseurs en janvier 2022 | | 57285 | |
| License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO Platform | | 54900 | |
| Levée dOption de Licence par AstraZeneca pour un Virus Oncolytique issu de la Plateforme Invir.IO | | 54900 | |
| Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgenes Invir.IO Platform | | 92432 | |
| Transgene annonce une levée doption de licence par AstraZeneca pour un virus oncolytique issu de sa plateforme Invir.IO | | 68928 | |
| TG4050, First positive clinical data from Phase I clinical trials | | 54900 | |
| TG4050, Premiers résultats positifs des essais de Phase I (en français) | | 54900 | |
| Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine | | 73059 | |
| Transgene et NEC annoncent des premiers résultats positifs des essais de Phase I de TG4050, un vaccin thérapeutique individualisé innovant contre le cancer | | 58199 | |
| annonceHome | | 54900 | |
| annonceHomeUS | | 54900 | |
| Icon | | 54900 | |
| TG4050 | | 54900 | |
| annonce substitut | | 54900 | |
| annonce | | 54900 | |
| Careers | | 54900 | |
| Annual General Meeting | | 54900 | |
| événements et presentations | | 54900 | |
| Analysts | | 54900 | |
| General | | 54900 | |
| Key figures | | 54900 | |
